Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.
Diabetes · 2024
Last updated 2026-05-28A 1993 study identified and described the human GLP-1 receptor, which helps control blood sugar and food intake. The research showed that a compound called exendin4(1-39) fully activated this receptor, while a related compound, exendin4(9-39), blocked its activity entirely.
AI summary of the abstract below.
| Journal | Diabetes, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.32 |
| NIH percentile | 20 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor involved in the regulation of blood glucose levels and food intake. Stabilized agonists targeting GLP-1R are used in the treatment of type 2 diabetes and have recently become a breakthrough obesity therapy. Here, we revisit a classic article in Diabetes by Thorens et al. that described the cloning, sequencing, and functional expression of the human GLP-1R. The article also demonstrated that exendin4(1-39) was a full agonist of the human GLP-1R whereas exendin4(9-39) was a full antagonist. We discuss how the knowledge imparted by these studies has gone on to inform multiple strands of GLP-1R biology over the past three decades, including pharmacology, signaling, human genetics, structural biology, and chemical biology.
Verbatim abstract via PubMed 38900951 ↗